New hope for Hard-to-Treat nasopharyngeal cancer: four drug cocktails enter trial

NCT ID NCT07070479

Recruiting now Disease control Sponsor: Ming-Yuan Chen Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase 2 trial tests four different drug combinations in 208 people with advanced nasopharyngeal cancer that has stopped responding to standard treatments, including immunotherapy. The goal is to see which combination best shrinks tumors and delays cancer growth. Participants will receive one of four regimens: ivonescimab alone, ivonescimab plus nimotuzumab, liposomal mitoxantrone plus an anti-PD-1 antibody, or liposomal irinotecan plus S-1.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ivonescimab, nimotuzumab, liposomal mitoxantrone, anti-PD-1 antibody, liposomal irinotecan, S-1
What this could lead to: If successful, this trial could identify a new treatment option for people with advanced nasopharyngeal cancer that no longer responds to standard immunotherapy.
What could go wrong: This is an early phase 2 trial with a small number of participants. The treatments may not work better than existing options, and side effects could be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT OR METASTATIC NASOPHARYNGEAL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

nasopharyngeal carcinoma Neoplasm Metastasis Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECURRENT OR METASTATIC NASOPHARYNGEAL CARCINOMA

Contacts and locations

Locations

Cancer Center of Guangzhou Medical University
NOT_YET_RECRUITING

Guangzhou, Guangdong, China
Guangdong Provincial People's Hospital
NOT_YET_RECRUITING

Guangzhou, Guangdong, China
Sun Yat-sen University Cancer Center
NOT_YET_RECRUITING

Guangzhou, Guangdong, China
The Fifth Affiliated Hospital of Sun Yat-sen University
RECRUITING

Zhuhai, Guangdong, China
Xiangya Hospital, Central South University
NOT_YET_RECRUITING

Changsha, Hunan, China
Zhongshan People's Hospital
NOT_YET_RECRUITING

Zhongshan, Guangdong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.